Comments
Suven Life Sciences Ltd (Suven) today said its clinical drug candidate SUVN-502 completed all the long-term chronic studies essential for US Food and Drug Authority (USFDA) to initiate human phase-II clinical trials. SUVN-502 has been tested in human Phase 1 trials in Switzerland and demonstrated to be very safe at all doses and durations tested.
The next stage will be proof of concept Phase II clinical trials in patients with Alzheimer's/Schizophrenia disease. The potential market opportunity is more than $20 billion globally said Mr Venkat Jasti, CEO of Suven Life Sciences, in a press release. “We have also received several interests for the product from pharmaceutical companies,” he added.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.